Bullish Moving Averages
16
Bearish Moving Averages
0
Back Stocks profile
Stock analysis tool for investors
Open an Account with Bigul in 5 minutes
Performance
Today’s low
6350.00Today’s High
6442.0052W low
3698.0052W High
7221.00Open Price
6369.00Prev. Close
6205.1500Volume
1911.00Value
12217118.55Fundamentals
Market Cap Cr
15982.60
Price to Earnings
99.00
Price to Book Value
22.50
Dividend Yield
0.30
PE to Growth
1.60
Op Revenue TTM Cr
1295.53
Net Profit TTM Cr
161.51
Cash From Operating Activity Cr
92.53
Return on Equity %
22.68
EMA & SMA
DELIVERY AND VOLUME
DAILY AVG. DELIVERY VOLUME %
02 Jul, 2024
57.8
Week
40
Month
41.9
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
6401.70
PIVOT
First Resistance
6503.10
Second Resistance
6642.30
Third Resistance
6743.70
First Support
6262.50
Second Support
6161.10
Third Support
6021.90
Relative Strength Index
57.51
Money Flow Index
58.35
MACD
120.58
MACD Signal
150.06
Average True Range
273.07
Average Directional Index
18.55
Rate of Change (21)
2.99
Rate of Change (125)
15.15
Commodity Channel Index
54.1
Williams %R
-68.3
BETA
1 Month
1.04
3 Month
1.04
1 Year
0.66
3 Year
0.29
PRICE CHANGE ANALYSIS
↑ 1.01%
1 Week
Low
High
6069.7
6999
↑ 3.46%
1 Month
Low
High
5468.05
6999
↑ 24.11%
3 Months
Low
High
4800.15
6999
↑ 12.2%
6 Months
Low
High
4785
7220.95
↑ 72.44%
1 Year
Low
High
3698.05
7220.95
| Indicator | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 391.86 | 315.45 | 319.44 | 303.57 | 292.70 | 257.00 | 242.92 | 236.45 | 235.65 | 205.86 | 200.55 | |
| Operating Expenses Qtr | 333.81 | 290.73 | 258.31 | 228.22 | 224.85 | 213.22 | 195.40 | 204.37 | 194.00 | 185.86 | 179.79 | |
| Operating Profit Qtr | 49.39 | 15.06 | 52.76 | 67.25 | 59.85 | 36.59 | 40.72 | 27.96 | 37.96 | 14.67 | 17.92 | |
| EBIDT Qtr Cr | 58.05 | 24.72 | 77.56 | 75.35 | 27.62 | 43.79 | 47.52 | 32.08 | 41.64 | 20.00 | 20.76 | |
| Depreciation Qtr | 3.76 | 3.70 | 3.67 | 3.80 | 4.25 | 4.13 | 3.29 | 4.59 | 4.41 | 3.51 | 4.28 | |
| Net Profit Qtr | 39.48 | 15.80 | 52.37 | 53.86 | 17.27 | 29.30 | 32.56 | 20.15 | 27.98 | 11.42 | 11.95 | |
| Basic EPS Qtr | 15.79 | 6.32 | 20.95 | 21.54 | 6.91 | 11.72 | 13.03 | 8.06 | 11.19 | 4.57 | 4.78 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 1330.33 | 1029.07 | 820.36 | 826.40 | 844.80 | |
| Operating Expenses Annual Cr | 1111.08 | 837.85 | 719.42 | 678.09 | 711.11 | |
| Operating Profit Annual | 184.45 | 165.12 | 86.18 | 135.47 | 120.70 | |
| Operating Profit Margin Annual % | 13.86 | 16.05 | 10.51 | 16.39 | 14.29 | |
| Total Expenses Annual Cr | 1127.22 | 854.74 | 737.32 | 699.31 | 730.83 | |
| EBIDT Annual Cr | 219.25 | 191.22 | 100.94 | 148.31 | 133.69 | |
| EBIDT Annual margin % | 16.48 | 18.58 | 12.30 | 17.95 | 15.83 | |
| Depreciation | 14.94 | 16.26 | 16.95 | 20.13 | 18.58 | |
| PAT Before ExtraOrdinary Items Annual Cr | 161.51 | 99.29 | 61.60 | 93.30 | 72.21 | |
| Net Profit Annual | 161.51 | 99.29 | 61.60 | 93.30 | 72.21 | |
| Basic EPS Annual | 64.60 | 39.70 | 24.60 | 37.30 | 28.90 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 711.92 | 588.69 | 511.39 | 456.17 | 364.44 | |
| Minority Interest Liability Annual Cr | - | - | - | - | - | |
| Total Non Current Liabilities Annual Cr | 8.99 | 12.25 | 12.52 | 15.04 | 14.68 | |
| Total Current Liabilities Annual Cr | 357.12 | 383.93 | 332.65 | 303.50 | 327.24 | |
| Total Capital Plus Liabilities Annual Cr | 1078.03 | 984.87 | 856.56 | 774.71 | 706.36 | |
| Fixed Assets Annual | 66.95 | 70.19 | 76.69 | 84.98 | 95.77 | |
| Total Non Current Assets Annual | 145.32 | 149.40 | 150.89 | 155.95 | 164.04 | |
| Total Current Assets Annual | 932.71 | 835.47 | 705.67 | 618.76 | 542.32 | |
| Total Assets Annual | 1078.03 | 984.87 | 856.56 | 774.71 | 706.36 | |
| Contingent Liabilities plus Commitments Annual Cr | - | 132.28 | 124.60 | 89.17 | 69.19 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | 92.53 | 58.29 | 100.80 | 104.78 | 87.42 | |
| Cash from Investing Activity Annual | 21.74 | 18.11 | 4.74 | 173.03 | -170.80 | |
| Cash from Financing Annual Activity | -44.37 | -24.48 | -9.46 | -8.97 | -6.36 | |
| Net Cash Flow Annual | - | 51.92 | 96.08 | 268.84 | -89.74 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 284.77 | 235.48 | 204.56 | 182.47 | 145.78 | |
| ROE Annual % | 22.68 | 16.86 | 12.04 | 20.45 | 19.81 | |
| ROCE Annual % | 28.34 | 29.11 | 16.03 | 27.20 | 30.36 | |
| Total Debt to Total Equity Annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EBDIT Annual Margin % | 16.92 | 19.06 | 12.52 | 18.22 | 16.07 |
| Indicator | Graph |
|---|---|
| Total Qtr Revenue cr | |
| Operating Expenses Qtr | |
| Operating Profit Qtr | |
| EBIDT Qtr Cr | |
| Depreciation Qtr | |
| Net Profit Qtr | |
| Basic EPS Qtr |
| Indicator | Graph |
|---|---|
| Total Revenue Annual | |
| Operating Expenses Annual Cr | |
| Operating Profit Annual | |
| Operating Profit Margin Annual % | |
| Total Expenses Annual Cr | |
| EBIDT Annual Cr | |
| EBIDT Annual margin % | |
| Depreciation | |
| PAT Before ExtraOrdinary Items Annual Cr | |
| Net Profit Annual | |
| Basic EPS Annual |
| Indicator | Graph |
|---|---|
| Total ShareHolders Funds Annual | |
| Minority Interest Liability Annual Cr | |
| Total Non Current Liabilities Annual Cr | |
| Total Current Liabilities Annual Cr | |
| Total Capital Plus Liabilities Annual Cr | |
| Fixed Assets Annual | |
| Total Non Current Assets Annual | |
| Total Current Assets Annual | |
| Total Assets Annual | |
| Contingent Liabilities plus Commitments Annual Cr |
| Indicator | Graph |
|---|---|
| Cash from Operating Activity Annual | |
| Cash from Investing Activity Annual | |
| Cash from Financing Annual Activity | |
| Net Cash Flow Annual |
| Indicator | Graph |
|---|---|
| Book Value Per Share Annual | |
| ROE Annual % | |
| ROCE Annual % | |
| Total Debt to Total Equity Annual | |
| EBDIT Annual Margin % |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| SHIVANI TEJAS TRIVEDI | 2.43 | 74540669 | - | - |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| AstraZeneca Pharmaceuticals AB | 75 | 74540651 | 0 | 0 |
| Name | Holding Percent | Holding Id |
|---|---|---|
| NIPPON LIFE INDIA TRUSTEE LTD - VARIOUS SCHEMES | 2.88 | 74540654 |
| Name | Holding Percent | Holding Id |
|---|---|---|
| TEJAS BHALCHANDRA TRIVEDI | 2.72 | 74540668 |
| SHIVANI TEJAS TRIVEDI | 2.43 | 74540669 |
| MINAXI BHALCHANDRA TRIVEDI | 1.84 | 74540670 |
| Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
| Jul 05, 2024 | 24 | FINAL | Jul 05, 2024 | Equity Share |
| Jul 14, 2023 | 16 | FINAL | Jul 14, 2023 | Equity Share |
| Jul 07, 2022 | 8 | FINAL | Jul 08, 2022 | Equity Share |
| Aug 18, 2021 | 2 | INTERIM | Aug 20, 2021 | Equity Share |
| Aug 20, 2020 | 2 | INTERIM | Aug 21, 2020 | Equity Share |
| Aug 20, 2019 | 1 | INTERIM | Aug 21, 2019 | Equity Share |
| Jul 09, 2012 | 3.5 | FINAL | - | Equity Share |
| Jul 07, 2011 | 10 | FINAL | - | Equity Share |
| May 06, 2010 | 10 | FINAL | - | Equity Share |
| Apr 29, 2009 | 15 | FINAL | - | Equity Share |
| Apr 11, 2008 | 15 | FINAL | - | Equity Share |
| Mar 22, 2007 | 12 | INTERIM | Mar 24, 2007 | Equity Share |
| Apr 12, 2006 | 20 | FINAL | - | Equity Share |
| Mar 18, 2005 | 50 | FINAL | - | Equity Share |
| Apr 16, 2004 | 3.9 | FINAL | - | Equity Share |
| Apr 17, 2003 | 3.7 | FINAL | - | Equity Share |
| May 15, 2002 | - | FINAL | - | Equity Share |
| Jun 18, 2001 | - | FINAL | - | Equity Share |
| Aug 11, 2000 | - | FINAL | - | Equity Share |
| Ex-Date | Split Ratio | Record Date |
|---|---|---|
| Jun 15, 2006 | 10:2 | 2006-06-22 |
| Ex-Date | Purpose | Notes |
|---|---|---|
| May 27, 2024 | Audited Results & Dividend | - |
| Feb 08, 2024 | Quarterly Results | - |
| Nov 09, 2023 | Quarterly Results | - |
| Aug 14, 2023 | Quarterly Results | - |
| May 30, 2023 | Audited Results & Dividend | - |
| Feb 10, 2023 | Quarterly Results | - |
| Nov 11, 2022 | Quarterly Results | - |
| Aug 08, 2022 | Quarterly Results | - |
| May 26, 2022 | Audited Results & Final Dividend | - |
| Feb 08, 2022 | Quarterly Results | - |
| Nov 09, 2021 | Quarterly Results | - |
| Aug 09, 2021 | Quarterly Results & Interim Dividend | - |
| May 25, 2021 | Audited Results | - |
| Feb 08, 2021 | Quarterly Results | - |
| Nov 05, 2020 | Quarterly Results | - |
| Aug 10, 2020 | Quarterly Results & Interim Dividend | - |
| May 18, 2020 | Audited Results | - |
| Feb 03, 2020 | Quarterly Results | - |
| Nov 11, 2019 | Quarterly Results | - |
| Aug 07, 2019 | Quarterly Results & Interim Dividend | - |
| May 24, 2019 | Audited Results | - |
| Feb 06, 2019 | Quarterly Results | - |
| Nov 13, 2018 | Quarterly Results | - |
| Aug 13, 2018 | Unaudited Financial Results | - |
| May 21, 2018 | Audited Results | - |
| Feb 05, 2018 | Quarterly Results | - |
| Nov 06, 2017 | Quarterly Results | - |
| Aug 08, 2017 | Quarterly Results | - |
| May 09, 2017 | Audited Results | - |
| Feb 02, 2017 | Quarterly Results | - |
| Dec 02, 2016 | Others | Mr. Rajesh Marwaha, Chief Financial Officer of the Company hasbeen inducted into the board as Additional and Whole-time Director. His profile is attached. |
| Nov 11, 2016 | Quarterly Results | - |
| Aug 09, 2016 | Quarterly Results | - |
| May 25, 2016 | Audited Results | - |
| Feb 06, 2016 | Quarterly Results & Others | The Board of Directors approved the re-appointment of Mr. Sanjay Murdeshwar as Managing Director of the Company for a period of 3 years, to be effective from May 02, 2016. |
| Dec 02, 2015 | Others | Decided to close the Active Pharmaceutical Ingredient Unit (API Unit) situated at 12th Mile on Bellary Road,Venkatala, Yelahanka, Bangalore - 560063. |
| Nov 06, 2015 | Quarterly Results & Others | The Board appointed Ms. Claire-Marie O' Grady as Director of the Company in the vacancy caused by the resignation of Ms. Rebekah Martin with immediate effect. |
| Aug 04, 2015 | Quarterly Results | - |
| May 27, 2015 | Audited Results | - |
| Feb 11, 2015 | Quarterly Results | - |
| Nov 03, 2014 | Quarterly Results | - |
| Aug 12, 2014 | Quarterly Results | - |
| May 30, 2014 | Audited Results | - |
| May 05, 2014 | Others | To consider seeking approval of shareholders of the Company through Postal Ballot, for the voluntary delisting proposed by AstraZeneca Pharmaceuticals AB Sweden,Promoter of the company. |
| Apr 15, 2014 | Others | To consider for the voluntary delisting proposed by AstraZeneca Pharmaceuticals Promoter of the Company, in terms of Securities and Exchange Board of India, through Postal Ballot. |
| Mar 15, 2014 | Others | To consider the voluntary delisting proposal from AstraZeneca Pharmaceuticals AB, Sweden in terms of their letter dated March 01, 2014 at the meeting of the BOD of the Company held on March 15,2014. |
| Mar 05, 2014 | Others | - |
| Feb 10, 2014 | Quarterly Results | - |
| Nov 11, 2013 | Quarterly Results | - |
| Aug 13, 2013 | Quarterly Results | - |
| May 21, 2013 | Audited Results | - |
| May 06, 2013 | Others | - |
| May 02, 2013 | Quarterly Results | - |
| Feb 06, 2013 | Quarterly Results | - |
| Nov 07, 2012 | Quarterly Results | - |
| Aug 10, 2012 | Quarterly Results | - |
| May 11, 2012 | Audited & Quarterly Results | - |
| Feb 02, 2012 | Quarterly Results | - |
| Nov 10, 2011 | Quarterly Results | - |
| Aug 08, 2011 | Quarterly Results | - |
| Jun 14, 2011 | Others | inter alia, to consider and approve the proposal of straightening of land boundaries of factory with IDL Industries Ltd. |
| May 13, 2011 | Audited Results & Dividend | Fifteen Months. |
| Feb 08, 2011 | Quarterly Results | - |
| Oct 27, 2010 | Quarterly Results | - |
| Jul 27, 2010 | Quarterly Results & Others | For seeking the consent / approval of the Shareholders of the Company through postal ballot to the delisting proposal initiated by AstraZeneca Pharmaceuticals, AB, Sweden, promoter of the Company. |
| Jul 09, 2010 | Others | The Board has deferred the decision on delisting proposal initiated by AstraZeneca Pharmaceuticals AB Sweden, promoter of the Company. |
| Jun 29, 2010 | Voluntary Delisting of Shares | To make a voluntary delisting offer to the public Shareholders of the Co. in accordance with the SEBI (DES) Regulations, 2009 with a view to delist the Equity Shares from BSE, NSE & BgSE. |
| Apr 27, 2010 | Others | The Board has appointed Ms. Anita Zutshi as the Chief Financial Officer of the Company. |
| Apr 26, 2010 | Quarterly Results | - |
| Mar 25, 2010 | Others | 1. Proposal to augment the Co's Tablet manufacturing plant and facility involving an estimated aggregate outlay of Rs. 70 Crs. 2. Appointment of Mr. Luigi Felice La Corte, as an Additional Director. |
| Feb 23, 2010 | Audited Results, Dividend & Others | The Board has approved the change in the accounting year of the Company from "January-December" to "April-March" & Recommended a Dividend of Rs. 10/- per Equity Share of face value of Rs. 2/- each. |
| Oct 27, 2009 | Quarterly Results | - |
| Jul 27, 2009 | Quarterly Results | - |
| Apr 23, 2009 | Quarterly Results | - |
| Feb 18, 2009 | Audited Results & Dividend | - |
| Oct 23, 2008 | Quarterly Results | - |
| Jul 29, 2008 | Quarterly Results | - |
| Apr 28, 2008 | Quarterly Results | - |
| Feb 25, 2008 | Audited Results & Dividend | - |
| Oct 26, 2007 | Quarterly Results | - |
| Jul 26, 2007 | Quarterly Results | - |
| Apr 30, 2007 | Quarterly Results | - |
| Mar 17, 2007 | Interim Dividend | To consider the approval of the revised Audited Accounts for the financial year ended December 31, 2006, after incorporating necessary changes as to the revocation of recommended dividend & others. |
| Feb 23, 2007 | Accounts & Dividend | - |
| Oct 28, 2006 | Quarterly Results | - |
| Sep 08, 2006 | Issue of fully paid bonus debentures | Inter alia, to consider a proposal for issue by the Company of secured fully paid bonus debentures from its General Reserve in terms of a Scheme of Arrangement between the Company and its Shareholders |
| Aug 28, 2006 | Issue of fully paid bonus debentures | To consider a proposal for issue by the Company of secured fully paid bonus debentures from its General Reserve in terms of a Scheme of Arrangement between the Company and its Shareholders. (deferred) |
| Jul 28, 2006 | Quarterly Results | - |
| May 09, 2006 | Sub Division of Equity shares | - |
| Apr 29, 2006 | Quarterly Results | - |
| Feb 23, 2006 | Accounts & Dividend | - |
| Oct 20, 2005 | Quarterly Results | (Revised) |
| Aug 24, 2005 | Accounts | - |
| Apr 27, 2005 | Quarterly Results | - |
| Feb 16, 2005 | Accounts & Dividend | (Revised) |
| Oct 30, 2004 | Quarterly Results | - |
| Aug 16, 2004 | Quarterly Results | - |
| May 31, 2004 | Quarterly Results | (Revised) |
| Apr 21, 2004 | Others | Mr. Bhasker V. Iyer was appinted as an additional Director and Managing Director w.e.f. 06-05-2004. |
| Mar 04, 2004 | Others | Astra Pharmaceuticals AB(APAB) a promoter of the company, held 56.50% of the voting share capital of the company in March, 2002. |
| Feb 24, 2004 | Dividend & Accounts | - |
| Nov 26, 2003 | Quarterly Results | - |
| Aug 26, 2003 | Quarterly Results | - |
| Apr 28, 2003 | Quarterly Results | - |
| Feb 27, 2003 | Dividend, Accounts & Quarterly Results | - |
| Oct 29, 2002 | Quarterly Results | - |
| May 28, 2002 | Quarterly Results | - |
| Mar 14, 2002 | Accounts & Dividend (9 months) | - |
| Oct 17, 2001 | Quarterly Results | - |
| Jul 30, 2001 | Quarterly Results | - |
| Jul 19, 2001 | Quarterly Results | (Cancelled) |
| May 17, 2001 | Qtr Results, Dividend & Accounts | - |
| Jan 18, 2001 | Quarterly Results | - |
| Oct 31, 2000 | Quarterly Results | - |
| Jul 12, 2000 | Quarterly Results | - |
| Mar 30, 2000 | Interim Dividend | - |
| Jan 29, 2000 | Quarterly Results | - |
| Jan 19, 2000 | Quarterly Results | - |
| Oct 22, 1999 | Quarterly Results | - |
| Jul 21, 1999 | Quarterly Results | - |
| Apr 20, 1999 | Quarterly Results | - |
| Jan 28, 1999 | Quarterly Results | - |
| Oct 27, 1998 | Quarterly Results | - |
| Jul 28, 1998 | Quaterly Results | - |
| Jun 26, 1998 | Accounts & Dividend | - |
| May 27, 1998 | Half Yearly Results | - |
| Nov 11, 1997 | Half Yearly Results | - |
| Jun 18, 1997 | Accounts & Dividend | - |
| Ex-Date | Bonus Ratio | Record Date |
|---|
01 Jul 2024
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
Please find the enclosed document of the Company as per the captioned subject for your reference.
27 Jun 2024
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable of SEBI (LODR) Regulations, 2015, we would like to inform you that the RTA of the Company have informed the Company on the enclosed request for Loss of Share Certificate from the claimant.
25 Jun 2024
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Record Date For Payment Of Final Dividend
Further to our intimation dated May 27, 2024, we wish to inform that the Record Date for determining the entitlement of the shareholders for the payment of Final Dividend for the financial year is July 5, 2024. The Final Dividend, if approved by the shareholders, shall be paid/ dispatched to the shareholders on or before September 6, 2024.
25 Jun 2024
AstraZeneca's Imfinzi fails in late-stage trial to treat lung cancer cases
Imfinzi is a human monoclonal antibody, which works to block a tumour's ability to evade and dampen the immune system, while also boosting the body's anti-cancer immune response
21 Jun 2024
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Please find the attached disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015.
17 Jun 2024
AstraZeneca chemotherapy gets US nod for certain type of endometrial cancer
Endometrial cancer ranks as the fourth most prevalent cancer among women in the US. In 2022, it affected more than 66,000 patients
14 Jun 2024
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (LODR) Regulations, 2015, we would like to inform you that the RTA of the Company, Integrated Registry Management Services Private Limited have informed the Company on the enclosed request for loss of share certificate from the legal representative of the claimant.
13 Jun 2024
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Closure of Trading Window
This is to inform you that in accordance with the provisions of SEBI (PIT) Regulations, 2015 read with AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading, the trading window for dealing in the equity shares of the Company will be closed from June 16, 2024 and the same shall reopen after 48 hours from the declaration of un-audited financial results of the Company for the quarter ending June 30, 2024.
07 Jun 2024
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith the certificate dated June 3, 2024 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
01 Jun 2024
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Appointment Of Senior Management Personnel
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we wish to inform you that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved the appointment of Ms. Shikha Mirchandani Chatrath as Director - Commercial Excellence, BD & Strategy with effect from June 17, 2024,
